Alvotech (ALVO) vs Recursion Pharmaceuticals (RXRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Alvotech (ALVO) has outperformed Recursion Pharmaceuticals (RXRX) over the past year, losing 34.7% versus a loss of 35.1%. Recursion Pharmaceuticals is the larger company by market cap ($2.28 billion vs $2.05 billion), about 1.1 times the size. Alvotech converts more of its revenue into profit, with a net margin of 4.8% versus -863.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALVO | RXRX |
|---|---|---|
| Share price | $5.74 | $4.26 |
| Market cap | $2.05B | $2.28B |
| 1-day change | +1.23% | +7.86% |
| YTD return | +10.53% | -3.42% |
| 1-year return | -34.68% | -35.14% |
| 5-year return | — | -79.25% |
| Forward P/E | 25.14 | — |
| EPS (TTM) | $-0.62 | $-1.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $586.32M | $74.68M |
| Revenue growth (YoY) | +19.74% | +26.92% |
| Net income (latest FY) | $27.92M | $-644.76M |
| Gross margin | 59.82% | 4.99% |
| Operating margin | 13.34% | -867.87% |
| Net margin | 4.76% | -863.35% |
| 52-week high | $9.05 | $7.18 |
| 52-week low | $2.94 | $2.77 |
| Distance from 52-week high | -36.54% | -40.67% |
| Analyst consensus | none | none |
| Avg. price target upside | +18.47% | +69.49% |
| Average volume | 1.05M | 20.70M |
| Shares outstanding | 356.82M | 535.34M |
| Employees | 1,279 | 600 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Alvotech is more profitable, keeping 4.8 cents of every revenue dollar as net income versus -863.4 cents for Recursion Pharmaceuticals.
- Recursion Pharmaceuticals grew revenue faster in its latest fiscal year (+26.92% vs +19.74%).
About Alvotech
ALVO stock →Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,279 employees
About Recursion Pharmaceuticals
RXRX stock →Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 600 employees
ALVO vs RXRX FAQ
Which is bigger, Alvotech or Recursion Pharmaceuticals?
Recursion Pharmaceuticals (RXRX) is larger, with a market capitalization of $2.28B compared with $2.05B for Alvotech (ALVO).
Which stock has performed better over the past year, ALVO or RXRX?
ALVO returned -34.68% over the past 12 months, compared with -35.14% for RXRX (price return, excluding dividends). Past performance does not predict future results.
Are Alvotech and Recursion Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.